Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in St. Stefan ob Stainz – page 26

426 clinical trials in St. Stefan ob Stainz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

St. Stefan ob Stainz at a glance
426
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

426 trials in St. Stefan ob Stainz

Open in trial search

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479
  • Sponsor:Boehringer Ingelheim Espana S.A.

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Study on the Effect of Amoxicillin on Post-Surgical Complications in Patients Undergoing Dental Implant Surgery with Bone Regeneration and Sinus Elevation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Medical University Of Graz

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Indenebart
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Study of Aflibercept 8mg for Patients with Neovascular Age-Related Macular Degeneration Previously Treated with Faricimab and Aflibercept 2mg

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Medical University Of Graz

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in St. Stefan ob Stainz

What the registry says about research in the country

01 Hepatology Research

Innovative clinical trials focusing on non-alcoholic steatohepatitis (NASH), investigating advanced therapeutic approaches for liver disease management. The research examines the effectiveness of semaglutide in improving liver health and preventing disease progression.

  • Liver Histology Improvement
  • Fibrosis Management
  • Clinical Event Prevention

This two-part study aims to evaluate both immediate histological improvements and long-term clinical outcomes in patients with moderate to advanced liver fibrosis.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.